Application of ferulic acid in anti-platelet aggregation

Under normal circumstances, the platelets in our peripheral blood are present in the blood in a scattered form. Platelet aggregation, which is actually a process of blood clotting, is a state in which only many platelets stick together. Essential thrombocythemia is a myeloproliferative disease characterized by bleeding tendency and thrombosis, persistently increased platelet counts in peripheral blood, abnormal function, and excessive proliferation of bone marrow megakaryocytes. As the disease often has repeated bleeding, it is also known as hemorrhagic thrombocytosis, more common in people over the age of 40.

In domestic statistics, 30% have arterial or venous thrombosis. After vascular embolization of the limbs, it can show numbness, pain, and even gangrene, as well as erythematous limb pain. Spleen and mesenteric vascular embolization can cause abdominal pain and vomiting. Lung, brain, and renal embolism cause corresponding clinical symptoms. Splenomegaly account for 80%, generally mild to moderate. A small number of patients have hepatomegaly. According to the degree of thrombocytosis, the course varies. Most cases progress slowly, with a median survival of 10 to 15 years. A small number of patients can be converted to myelofibrosis, polycythemia vera or chronic myelogenous leukemia. Vital organs have thrombosis and bleeding are often the main cause of death.

At present, in terms of anticoagulant selection, aspirin (ASP) has a positive effect, low price, and is recommended as the preferred anticoagulant. However, patients may also experience ASP resistance and other adverse reactions.

In order to find new anti-platelet aggregation drugs, medical experts have synthesized six β-alanine derivatives of Tetramethylpyrazine Aromatic Acid Ether with tetramethylpyrazine, β-alanine and ferulic acid as starting materials. The pharmacological results showed that the platelet inhibition rates of the 6 target compounds were 6.4%, 27.4%, 7.7%, 14.8%, 37.0%, and 10.9%, respectively. Further study found that many of them could reduce the thrombotic event by 23%, and the platelet aggregation rate significantly decreased after one month of experimental treatment (P<0.01).